Context Therapeutics (CNTX) Non-Current Assets (2020 - 2026)
Context Therapeutics (CNTX) posted Non-Current Assets of $342277.0 for Q1 2026, up 144.37% sequentially from $140066.0 in Q4 2025, and up 45.86% YoY from $234656.0 in Q1 2025.
Context Therapeutics (CNTX) Non-Current Assets (2020 - 2026) Analysis & Trends
Context Therapeutics has reported Non-Current Assets for 7 years, with the latest figure at $342277.0 in Q1 2026.
- Quarterly Non-Current Assets rose 45.86% year-over-year to $342277.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $858552.0 (up 16.83% YoY) and the FY2025 annual result came in at $140066.0, down 39.31% from the prior year.
- Non-Current Assets rose to $342277.0 in Q1 2026 per CNTX's latest filing, from $140066.0 in the prior quarter.
- Over five years, Non-Current Assets peaked at $342277.0 in Q1 2026 and troughed at $10388.0 in Q2 2024.
- A 5-year average of $141274.3 and a median of $143827.0 in 2022 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2022 and 2025: Non-Current Assets sank 92.11% in 2022, then jumped 1862.51% in 2025.
- Over 5 years, Non-Current Assets stood at $112285.0 in 2022, then plunged by 86.17% to $15524.0 in 2023, then surged by 1386.57% to $230775.0 in 2024, then slumped by 39.31% to $140066.0 in 2025, then soared by 144.37% to $342277.0 in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $342277.0, $140066.0, and $172343.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 938.60 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 468.65 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 18.06 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 6.80 Bn |
| 10 | Context Therapeutics | 49.23 Mn | 49.23 Mn | - | 315,292.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 315,292.00 |
| Mar 31, 2026 | 342,277.00 |
| Dec 31, 2025 | 140,066.00 |
| Sep 30, 2025 | 172,343.00 |
| Jun 30, 2025 | 203,866.00 |
| Mar 31, 2025 | 234,656.00 |
| Dec 31, 2024 | 230,775.00 |
| Sep 30, 2024 | 259,028.00 |
| Jun 30, 2024 | 10,388.00 |
| Mar 31, 2024 | 12,956.00 |
| Dec 31, 2023 | 15,524.00 |
| Sep 30, 2023 | 18,092.00 |
| Jun 30, 2023 | 52,703.00 |
| Mar 31, 2023 | 80,455.00 |
| Dec 31, 2022 | 112,285.00 |
| Sep 30, 2022 | 143,827.00 |
| Jun 30, 2022 | 196,956.00 |
| Mar 31, 2022 | 175,466.00 |
| Dec 31, 2021 | 50,389.00 |
| Sep 30, 2021 | 1.82 Mn |